Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.

Slides:



Advertisements
Similar presentations
Essential Documentation GCP Training Seminar 12th October 2011
Advertisements

CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
Chicken Soup for the Busy Coordinator
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
EDRN’s Validation Study Information Management System Developed for EDRN by the DMCC Cancer Biomarkers Group Division of Cancer Prevention Jet Propulsion.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Stanley Estime, MSCI December 9, 2014 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
By: Farzad Dadgari Soil and Environmental Specialist SWHISA.
Nikki Dillard Allison Lowry Tiffany Thomas.  “The maintenance of a history of one’s activities, as financial dealings, by entering data into ledgers.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Planning and Surviving An Audit/Monitoring visit Carmen B. Jacobs, BS, RN,OCN, CCRP U.T. MD Anderson Cancer Center Houston, Texas U.S.A.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Ensuring Human Subject Protection A Guide for Those who Obtain Research Informed Consent Documents 10/15/20151.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
Expedited Review – Retrospective studies: A New Path Stephanie Gentilin, MA, CCRAKatherine Bright Director SCTR SUCCESS Center, eIRB Team MemberIRB, Grants.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Stanley Estime, MSCI October 19, 2015 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
How to Start An Industry Sponsored Clinical Trial
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Session 6: Data Flow, Data Management, and Data Quality.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Good Clinical Practices and Best Research Practices at MU Health Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic.
Good Laboratory Practice
Medical Documentation CHAPTER 17. Purposes of Documentation  Communication  Most patients receive care from more than one source  Allows all health.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Informed Consent Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.
Data Management: Source Documents, Case Report Forms and Electronic Data Thomas Salerno, RN BSN MA Senior Team Lead Cardiology Research Jefferson Clinical.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Good Clinical Practice (GCP) and Monitoring Practices
The Role and Responsibilities of the Clinical Research Coordinator
Stephanie Oppenheimer, MS SUCCESS Center Erica Ellington, CRA, CHRC
MAINTAINING THE INVESTIGATOR’S SITE FILE
IRB reporting updates.
Alyssa Speier, MS, CIP November 13, 2013
EDRN’s Validation Study Information Management System
Catherine Gregor, MBA, CCRC, CCRP CRC Workshop August 1, 2014
Regulatory Binder: Maintaining Essential Study Documentation
Elements of an Organized Regulatory Binder
Basics of Building and Understanding Data Collection Forms
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Understanding the Process of Documenting Informed Consent
Protocol Approval Criteria
Good clinical practice
Presentation transcript:

Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance

Overview  Research design and purpose  Importance of validity and reliability  Multiple stakeholders, purposes and processes  Source Documentation  How to make corrections or appropriately document unexpected or adverse events or errors

Anatomy of Clinical Trial Research  Regardless of source (internal or sponsor) primary components include:  Research question – the “So What”  Significance – provides the context  Design – complex and multiple types  Study population – specific target  Variables – what is being measured  Data management and analysis  Maintaining validity and reliability for each component is crucial

Documentation regarding the study population  Essential that protocol defines the specific inclusion and exclusion criteria  Population estimate needs to be as accurate as possible  If documentation validating each subject’s inclusion and exclusion criteria is not complete AND accurate, the entire research study is jeopardized

Documentation regarding treatment/intervention  Also essential that the protocol provides clear and detailed explanation of the treatment/intervention for all arms or phases of the trial  Failure to adhere to the precision provided in the protocol for each study participant will invalidate the data and jeopardize the research

Why is monitoring clinical trials important?  To ensure the intervention is not unexpectedly harmful  If unexpectedly effective, not to delay next steps  Discontinue if no possibility of addressing research question  To ensure study sites are providing ethical interventions while maintaining the reliability and validity of the research

Who cares about your documentation?  Principal Investigator (PI)  Patient(s)  IRB  Corporate Compliance  Sponsor  FDA  Other regulatory bodies/organizations  Insurance companies/third party payors

What is Source Documentation Original documents, certified records of original data, records of clinical findings, observations, or other activities necessary for the reconstruction and evaluation of the study Examples: hospital records, clinical and office charts, laboratory results, subjects’ diaries, evaluation checklists, pharmacy dispensing records, x-rays, MRI, etc.

Source Documentation 21 CFR , 511.1(b)(7)(ii) and , state the clinical investigator must retain records required to be maintained under part 312, § 511.1(b), and part 812, for a period of time specified in these regulations. This requirement applies to the retention of the original source document, or a copy of the source document.

Case Report Forms The document provided by the sponsor or created by the PI for the collection of specific data to evaluate the study including adverse events. Data may be entered directly onto the case report forms. The case report form would then be considered a source document. This form should be signed and dated by the person who has collected the information to verify the information is accurate. Case report forms should NOT contain the subject’s name or SSN.

Electronic Data Capture as Source  Secure log in  Must be secure (HIPAA compliant for PHI)  Be able to indicate who completed the task (verification by the actual responsible person)  Can have built in checks/flags  Can serve as source for certain data points  SOP required indicating responsibilities for creating, modifying, maintaining and transmitting  Verify with sponsor if considered source

The Goal: Concise, complete, accurate, and consistent data that covers all data/information needed for the study Consider: What data points are needed for the final analysis What needs to be covered for compliance with the regulations

What needs to be documented? If it is not documented, it is not done  Consent  Inclusion/exclusion criteria  Randomization  All Data points for each study visit  Unanticipated events :  Unexpected (not in supporting documents/ different frequency or severity )  Potentially related (previous medical history)  Potential for harm

Data Points  Check protocol  Table of events  Specific instructions for processing or preforming tasks  Check consent  Check any specific manuals for processing  Space or place for interpretation (i.e. lab values for clinical significance)

Considerations  Use chronological order of visit  Place in order that is easy to follow  Consider page numbers  Place subject ID on the top of each page  Consider the version number (match to protocol)  Update as protocol is updated  Check boxes may require supporting documentation  Do not use abbreviations unless defined or standard

Filling out Source Docs  Who can do what (credentialing)  Complete in a timely manner (same day/visit)  Fill out headers  No Blank Pages!  Indicate if not done and why  Record data even if it is not the expected result  Must be readable – Do Not recopy for neatness  Late entries must be indicated as such  Source Documents must NOT be DISCARDED

Corrections  Do Not use white out  Do Not scribble over errors erase  Always use a pen (not pencil)  Line through error  Initial and date  Write in correction  Initial and date any late additions  Addendum to EMR

Notes to file When to use  Indicate information is stored elsewhere  Clarifies across the study When NOT to use  To replace source documentation  To explain numerous deviations Alternatives: Source documentation Correspondence with the sponsor/monitor